Difference between revisions of "Acute myeloid leukemia trial demographics"
Jump to navigation
Jump to search
(Created page with "{| class="wikitable sortable" style="width: 100%; text-align:center;" !style="width: 17%"|Study !style="width: 15%"|Arm !style="width: 17%"|Age, median (range) !style="width:...") |
m |
||
| Line 51: | Line 51: | ||
|[http://www.bloodjournal.org/content/118/14/3832.long ADcomparison] | |[http://www.bloodjournal.org/content/118/14/3832.long ADcomparison] | ||
|[[Acute_myeloid_leukemia#7.2B3d_.28standard-dose.29|7+3d (standard-dose)]] | |[[Acute_myeloid_leukemia#7.2B3d_.28standard-dose.29|7+3d (standard-dose)]] | ||
| − | |43 (15-60) | + | |43 (15-60)<sup>a</sup> |
|48/52 | |48/52 | ||
|NR | |NR | ||
| Line 58: | Line 58: | ||
|[http://www.bloodjournal.org/content/118/14/3832.long ADcomparison] | |[http://www.bloodjournal.org/content/118/14/3832.long ADcomparison] | ||
|[[Acute_myeloid_leukemia#7.2B3d_.28high-dose.29|7+3d (high-dose)]] | |[[Acute_myeloid_leukemia#7.2B3d_.28high-dose.29|7+3d (high-dose)]] | ||
| − | |43 (15-60) | + | |43 (15-60)<sup>a</sup> |
|60/40 | |60/40 | ||
|NR | |NR | ||
| Line 64: | Line 64: | ||
|- | |- | ||
|} | |} | ||
| − | + | ''<sup>a</sup>Age is not reported separately by arm. | |
[[Category:General reference pages]] | [[Category:General reference pages]] | ||
Revision as of 22:05, 18 January 2023
| Study | Arm | Age, median (range) | Sex (%M/%F) | Race | Performance Status |
|---|---|---|---|---|---|
| Wiernik et al. 1992 | 7+3d (standard-dose) | 55 (NR) | 57/43 | NR | ECOG 0-1: 86% |
| Wiernik et al. 1992 | 7+3i | 56 (NR) | 56/44 | NR | ECOG 0-1: 87% |
| ECOG E1900 | 7+3d (standard-dose) | 47 (17-60) | 52/48 | NR | NR |
| ECOG E1900 | 7+3d (high-dose) | 48 (18-60) | 50/50 | NR | NR |
| HOVON 43 AML/SAKK 30/01 | 7+3d (standard-dose) | 67 (60-79) | 57/43 | NR | ECOG 0-1: 88% |
| HOVON 43 AML/SAKK 30/01 | 7+3d (high-dose) | 67 (60-83) | 53/47 | NR | ECOG 0-1: 88% |
| ADcomparison | 7+3d (standard-dose) | 43 (15-60)a | 48/52 | NR | KPS 90-100%: 80% |
| ADcomparison | 7+3d (high-dose) | 43 (15-60)a | 60/40 | NR | KPS 90-100%: 82.5% |
aAge is not reported separately by arm.